WO2008100669A1 - Method and system for remotely administering a diuretic therapy - Google Patents
Method and system for remotely administering a diuretic therapy Download PDFInfo
- Publication number
- WO2008100669A1 WO2008100669A1 PCT/US2008/051179 US2008051179W WO2008100669A1 WO 2008100669 A1 WO2008100669 A1 WO 2008100669A1 US 2008051179 W US2008051179 W US 2008051179W WO 2008100669 A1 WO2008100669 A1 WO 2008100669A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diuretic
- patient
- algorithm
- server
- communication device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
- A61B5/1113—Local tracking of patients, e.g. in a hospital or private home
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0537—Measuring body composition by impedance, e.g. tissue hydration or fat content
Definitions
- This disclosure relates generally to a method and system for administering a diuretic therapy to a remotely located patient.
- a diuretic is substance that elevates the rate of urine excretion.
- Diuretics are commonly used to treat conditions such as heart failure, liver cirrhosis, hypertension and kidney diseases.
- CHF congestive heart failure
- edema which is the swelling of an organ or tissue due to the accumulation of intercellular fluid.
- Diuretics can therefore be administered to reduce the pathological edema by causing sodium and water loss through the urine.
- titration The process of gradually adjusting the dosage of a medication until the desired effect is achieved is referred to as "titration".
- Diuretic medications are particularly difficult to titrate because the dosage must frequently be adjusted based on criteria such as the patient's activity level, diet and overall health, and the dosage levels of other administered medications. This is particularly problematic in the field of home healthcare wherein the patient generally receives less direct supervision.
- a diuretic titration system includes a server having an algorithm, a communication device operatively connected to the server, and a monitoring device operatively connected to the server.
- the algorithm is configured to evaluate input from the communication device and/or the monitoring device in order to provide a diuretic dosage recommendation for a remotely located patient.
- a diuretic titration system in another embodiment, includes a server having an algorithm, a communication device operatively connected to the server, a monitoring device operatively connected to the server, an electronic medical record transferable to the algorithm, and an evidence based guideline transferable to the algorithm.
- the algorithm is configured to evaluate input from the communication device, the monitoring device, the electronic medical record, and/or the evidence based guideline in order to provide a diuretic dosage recommendation for a remotely located patient.
- a method for monitoring and regulating the dosage of a diuretic medication administered to a remotely located patient includes obtaining information pertaining to the remotely located patient, transmitting the information to a server, implementing the server to evaluate the information and provide a diuretic dosage recommendation for a the remotely located patient, and conveying the diuretic dosage recommendation to the remotely located patient.
- FIGURE 1 is a schematic diagram illustrating a diuretic titration system
- FIGURE 2 is a block diagram illustrating an exemplary algorithm of the titration system of Figure 1.
- FIGURE 3 is a block diagram illustrating an exemplary method for providing a diuretic dosage recommendation in response to input from a monitoring device.
- a diuretic titration system 10 is shown.
- the diuretic titration system 10 will hereinafter be described in accordance with an exemplary embodiment wherein the diuretic titration system 10 is configured to monitor and regulate the dosage of a remotely located patient 12 being treated in their home 14. It should, however, be appreciated that the diuretic titration system 10 may be implemented for any application wherein a diuretic medication is being remotely administered, monitored and/or regulated.
- the term "remotely located patient” may be defined to include any patient being treated or cared for outside a conventional hospital facility.
- the diuretic titration system 10 includes a communication device 16 and a monitoring device 18 disposed within the patient's home 14.
- the diuretic titration system 10 also includes a server 20 disposed in a hospital or clinic 22.
- a "server” may be defined to include any remotely accessible device comprising a processor.
- the server 20 is remotely connected to the communication device 16 and the monitoring device 18 in a conventional manner.
- the server 20 includes an algorithm 24 adapted to receive input from the communication device 16, the monitoring device 18, any electronic medical records (EMR) 26, and/or the evidence based guidelines 28.
- the algorithm 24 is also adapted to transmit output to the communication device 16 in order to communicate with the patient 12.
- the communication device 16 may include any device adapted to transfer information to and/or receive data from the patient 12 such as, for example, a telephone, a computer, a personal digital assistant (PDA), etc.
- the communication device 16 includes a telephone comprising interactive voice response (IVR) technology. IVR allows a user to select options from a voice menu and thereby interact with a computer via a telephone system. IVR systems generally play a pre-recorded voice prompt to which the user responds by pressing a number on a telephone keypad.
- IVR interactive voice response
- an exemplary IVR telephone system may be programmed to ask one or more of the following questions: is the patient experiencing a shortness of breath?; is the patient experiencing any swelling?; does the patient have a rash?; is the patient experiencing hearing loss?; has the patient consumed any foods or beverages with a high sodium content?
- the patient 12 may, for example, reply in the affirmative by pressing the number "1" on the telephone keypad, and may reply in the negative by pressing the number "2" on the telephone keypad. Any information input into the communication device 16 by the patient 12 is transferable to the server 20.
- the monitoring device 18 is operatively connectable to the patient 12.
- the monitoring device 18 may include, for example, pressure sensors adapted to weigh the patient 12 and/or motion sensors adapted to monitor patient activity level.
- the monitoring device 18 may also include a bioimpedance device adapted to estimate the patient's water content. Any data recorded by the monitoring device 18 is transferable to the server 20.
- the electronic medical record (EMR) 26 contains medical information pertaining to the patient 12.
- EMR data relevant to a dosage recommendation for a diuretic medication may include, for example, the patient's diagnosis; the currently prescribed diuretic dosage; other prescribed medications and their corresponding dosages; the patient's medical history including any previously prescribed medications and dosages; and the patient's dry or benchmark weight. This type of EMR 26 data is made available to the algorithm 24 as it may impact the selection of an appropriate diuretic dosage.
- EMR 26 data may be implemented by the algorithm 24 to select an appropriate diuretic dosage.
- EMR 26 information pertaining to other prescribed medications and their corresponding dosages may be relevant because the drug interaction may alter the effectiveness of diuretic medications.
- the patient's medical history including any previously prescribed medications and dosages may be relevant if, for example, the medical history reveals an atypical sensitivity to or tolerance of certain diuretic medications.
- the patient's dry or benchmark weight can be used to identify a sudden weight gain, which may be indicative of a pathological edema and may require a diuretic dosage increase.
- the evidence-based guidelines 28 include a comprehensive set of instructions adapted to guide decisions in specific areas of healthcare.
- the guidelines 28 are transferred to the algorithm 24 in certain instances to define or supplement the logic on which a diuretic dosage recommendation is based.
- the guidelines 28 are directly incorporated into the algorithm 24 such that the algorithm 24 itself reflects the logic of the guidelines 28.
- the term "logic" can be defined to include the specific manner in which the algorithm 24 evaluates input data for purposes of generating diuretic dosage recommendations.
- the algorithm 24 may comprise a variety of different forms of logic configured to evaluate input data in accordance with any known methodology for providing diuretic dosage recommendations.
- the algorithm 24 may incorporate logic from and provide diuretic dosage recommendations based on previously conducted medical research, the evidence-based guidelines 28, and/or a physician's personal experience with a given patient.
- Figures 2-3 provide more specific examples of methods that may be incorporated into the algorithm 24 in order to provide an appropriate diuretic dosage recommendation.
- a flow chart illustrates a method 100 for providing a diuretic dosage recommendation in response to input from the communication device 16 (shown in Figure 1).
- the individual blocks of the flow chart represent steps that may be performed in accordance with the method 100. Unless otherwise specified, the steps 102-116 need not be performed in the order shown.
- the method 100 evaluates input from the communication device 16 (shown in Figure 1) to determine if the patient 12 (shown in Figure 1) is experiencing any swelling. If at step 102 the patient 12 is experiencing swelling, the method 100 proceeds to step 104 wherein the diuretic dosage is increased. After step 104, the method 100 proceeds to step 106. If at step 102 the patient 12 is not experiencing swelling, the method 100 proceeds directly to step 106.
- the method 100 evaluates input from the communication device 16 (shown in Figure 1) to determine if the patient 12 (shown in Figure 1) has a rash. If at step 106 the patient 12 has a rash, the method 100 proceeds to step 108 wherein the diuretic dosage is decreased. After step 108, the method 100 proceeds to step 110. If at step 106 the patient 12 does not have a rash, the method 100 proceeds directly to step 110.
- the method 100 evaluates input from the communication device 16 (shown in Figure 1) to determine if the patient 12 (shown in Figure 1) is experiencing hearing loss. If at step 106 the patient 12 has hearing loss, the method 100 proceeds to step 112 wherein the diuretic dosage is decreased. After step 112, the method 100 proceeds to step 114. If at step 110 the patient 12 does not have hearing loss, the method 100 proceeds directly to step 114.
- the method 100 evaluates input from the communication device 16 (shown in Figure 1) to determine if the patient 12 (shown in Figure 1) has recently consumed any high sodium products. If at step 114 it is determined that the patient 12 has recently consumed a high sodium product, the method 100 proceeds to step 116 wherein the diuretic dosage is increased. After step 116, the method 200 returns to step 102. If at step 114 it is determined that the patient 12 has not consumed any high sodium products, the method 100 returns to step 102.
- a flow chart illustrates a method 200 for providing a diuretic dosage recommendation in response to input from the monitoring device 18 (shown in Figure 1).
- the individual blocks of the flow chart represent steps that may be performed in accordance with the method 200. Unless otherwise specified, the steps 202-212 need not be performed in the order shown.
- the method 200 evaluates input from the monitoring device 18 (shown in Figure 1) to determine if the patient 12 (shown in Figure 1) has gained weight. If at step 202 the patient 12 has gained weight, the method 200 proceeds to step 204 wherein the diuretic dosage is increased. After step 204, the method 200 proceeds to step 206. If at step 202 the patient 12 has not gained weight, the method 200 proceeds directly to step 206.
- the method 200 evaluates input from the monitoring device 18 (shown in Figure 1) to determine if the patient 12 (shown in Figure 1) has been sufficiently active. If at step 202 the patient 12 has not been sufficiently active, the method 200 proceeds to step 208 wherein the diuretic dosage is increased. After step 208, the method 200 proceeds to step 210. If at step 206 the patient 12 has been sufficiently active, the method 200 proceeds directly to step 210.
- the method 200 evaluates input from the monitoring device 18 (shown in Figure 1) to determine if the water content of the patient 12 (shown in Figure 1) has increased. If at step 202 the patient's water content has increased, the method 200 proceeds to step 212 wherein the diuretic dosage is increased. After step 212, the method 200 returns to step 202. If at step 210 the patient's water content has not increased, the method 200 returns to step 202.
- the magnitude and rate at which dosage is increased or decreased may, for example, be predicated on information from the EMR 26 (e.g., the patient's weight, sex, etc.) and on information from the evidence based guidelines 28 (shown in Figure 1). Limits corresponding to maximum diuretic dosages, and maximum rates for increasing and decreasing diuretic dosages may be established as a precautionary measure.
- Additional logic may be incorporated into the algorithm 24 to address conflicting dosage recommendations from steps 104, 108, 112 and 116 of Figure 2, and steps 204, 208 and 212 of Figure 3.
- steps 104 and 112 may respectively recommend both an increase and a decrease in diuretic dosage.
- the algorithm 24 may be configured to address conflicting dosage recommendations, for example, by assigning greater weight to one of the symptoms or by assessing the severity of the symptoms such that only one recommendation is ultimately conveyed to the patient 12.
- a healthcare provider such as the clinician 30 can be alerted when there are conflicting dosage recommendations so that the healthcare provider can evaluate the underlying information and make an appropriate recommendation.
- the algorithm 24 can convey such recommendation to the remotely located patient 12 via the communication device 16.
- the algorithm 24 may be configured to call the patient 12 and verbally convey a recommendation to either increase or decrease diuretic dosage.
- the algorithm 24 may be configured to send the patient 12 an e-mail conveying the recommendation to either increase or decrease diuretic dosage.
- the dosage recommendation and any data on which the recommendation is based may initially be conveyed to the clinician 30. Thereafter, the clinician 30 has the opportunity to evaluate and override the recommendation before it is conveyed to the patient 12. While the clinician 30 is depicted as being within the hospital 22, it should be appreciated that the clinician 30 may also be remotely located. As an example, the algorithm 24 may convey a dosage recommendation to a remotely located clinician via a cell phone or PDA. Thereafter, the remotely located clinician can call or otherwise contact the patient 12 if a dosage modification is appropriate.
- the diuretic titration system 10 can provide an optimal diuretic dosage for each patient without requiring office visits or any other form of direct supervision. Therefore, remotely located patients can receive a high level of care and avoid potentially costly exacerbation of the disease. Additionally, as the diuretic titration system 10 is at least partially automated, a single clinician 30 can conveniently monitor a large number of patients without having to physically visit each one.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Physiology (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0913333.1A GB2458614B (en) | 2007-02-12 | 2008-01-16 | Method and system for remotely administering a diuretic therapy |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/673,935 US7792689B2 (en) | 2007-02-12 | 2007-02-12 | Method and system for remotely administering a diuretic therapy |
| US11/673,935 | 2007-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008100669A1 true WO2008100669A1 (en) | 2008-08-21 |
Family
ID=39512544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2008/051179 Ceased WO2008100669A1 (en) | 2007-02-12 | 2008-01-16 | Method and system for remotely administering a diuretic therapy |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US7792689B2 (en) |
| GB (1) | GB2458614B (en) |
| WO (1) | WO2008100669A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8688467B2 (en) * | 2009-01-09 | 2014-04-01 | Cerner Innovation, Inc. | Automated analysis of data collected by in-vivo devices |
| US20120203573A1 (en) | 2010-09-22 | 2012-08-09 | I.D. Therapeutics Llc | Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns |
| US8827930B2 (en) * | 2011-01-10 | 2014-09-09 | Bioguidance Llc | System and method for patient monitoring |
| EP2727071A4 (en) | 2011-07-01 | 2015-08-12 | Baxter Corp Englewood | Systems and methods for intelligent patient interface device |
| US20140278468A1 (en) | 2013-03-15 | 2014-09-18 | I.D. Therapeutics Llc | Apparatus and method for optimizing treatment using medication compliance patterns and glucose sensor |
| EP3159845A1 (en) * | 2014-06-20 | 2017-04-26 | Nec Corporation | Monitoring device, monitoring system, monitoring method, and program |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6409662B1 (en) * | 1997-10-28 | 2002-06-25 | Alere Medical, Inc. | Patient interface system |
| US20040034286A1 (en) * | 2000-11-06 | 2004-02-19 | Kasper Edward K. | Method and system for outpatient monitoring |
| US20040260478A1 (en) * | 2001-08-03 | 2004-12-23 | Schwamm Lee H. | System, process and diagnostic arrangement establishing and monitoring medication doses for patients |
| US20050043965A1 (en) * | 2001-11-28 | 2005-02-24 | Gabriel Heller | Methods and apparatus for automated interactive medical management |
| US20050137481A1 (en) * | 2003-12-18 | 2005-06-23 | Paul Sheard | Monitoring method and apparatus |
| US20060010090A1 (en) * | 2004-07-12 | 2006-01-12 | Marina Brockway | Expert system for patient medical information analysis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6014626A (en) * | 1994-09-13 | 2000-01-11 | Cohen; Kopel H. | Patient monitoring system including speech recognition capability |
| US6980958B1 (en) | 2000-01-11 | 2005-12-27 | Zycare, Inc. | Apparatus and methods for monitoring and modifying anticoagulation therapy of remotely located patients |
| KR20030014387A (en) * | 2001-02-08 | 2003-02-17 | 인버니스 메디칼 리미티드 | A personal condition management system |
| US20020194221A1 (en) * | 2001-05-07 | 2002-12-19 | Strong Philip C. | System, method and computer program product for collecting information utilizing an extensible markup language (XML) framework |
| US7267830B2 (en) * | 2003-12-19 | 2007-09-11 | Alcon, Inc. | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision |
| US8078278B2 (en) * | 2006-01-10 | 2011-12-13 | Remon Medical Technologies Ltd. | Body attachable unit in wireless communication with implantable devices |
-
2007
- 2007-02-12 US US11/673,935 patent/US7792689B2/en active Active
-
2008
- 2008-01-16 WO PCT/US2008/051179 patent/WO2008100669A1/en not_active Ceased
- 2008-01-16 GB GB0913333.1A patent/GB2458614B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6409662B1 (en) * | 1997-10-28 | 2002-06-25 | Alere Medical, Inc. | Patient interface system |
| US20040034286A1 (en) * | 2000-11-06 | 2004-02-19 | Kasper Edward K. | Method and system for outpatient monitoring |
| US20040260478A1 (en) * | 2001-08-03 | 2004-12-23 | Schwamm Lee H. | System, process and diagnostic arrangement establishing and monitoring medication doses for patients |
| US20050043965A1 (en) * | 2001-11-28 | 2005-02-24 | Gabriel Heller | Methods and apparatus for automated interactive medical management |
| US20050137481A1 (en) * | 2003-12-18 | 2005-06-23 | Paul Sheard | Monitoring method and apparatus |
| US20060010090A1 (en) * | 2004-07-12 | 2006-01-12 | Marina Brockway | Expert system for patient medical information analysis |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2458614A (en) | 2009-09-30 |
| GB2458614B (en) | 2011-12-14 |
| US20080195414A1 (en) | 2008-08-14 |
| GB0913333D0 (en) | 2009-09-16 |
| US7792689B2 (en) | 2010-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | Patient characteristics and telemedicine use in the US, 2022 | |
| Mehrotra et al. | Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease | |
| Celler et al. | Using information technology to improve the management of chronic disease | |
| US7792689B2 (en) | Method and system for remotely administering a diuretic therapy | |
| Korevaar et al. | When to initiate dialysis: effect of proposed US guidelines on survival | |
| US9183720B2 (en) | Interactive medical device monitoring and management system | |
| US9076315B2 (en) | Interactive remote disease monitoring and management system | |
| US10120979B2 (en) | Predicting glucose trends for population management | |
| Steiner et al. | Hypertension care during the COVID‐19 pandemic in an integrated health care system | |
| Bednarski et al. | Assessment of ileostomy output using telemedicine: a feasibility trial | |
| Collins et al. | Comparison and survival of hemodialysis and peritoneal dialysis in the elderly | |
| Miller et al. | Telemedicine services provided to medicare beneficiaries by otolaryngologists between 2010 and 2018 | |
| WO2021247557A1 (en) | Artificial intelligence and/or machine learning based systems, devices, and methods for designing patient prescriptions | |
| Frankel et al. | Management of adults with diabetes on dialysis: Summary of recommendations of the Joint British Diabetes Societies guidelines 2022 | |
| Nakamoto et al. | Peritoneal dialysis care by using artificial intelligence (AI) and information technology (IT) in Japan and expectations for the future | |
| WO2014088933A1 (en) | Interactive medical device monitoring and management system | |
| Tsang | A rrow physicians: Are economics and medicine philosophically incompatible? | |
| CN119541747A (en) | A rare disease follow-up data processing system | |
| Reamer et al. | Continuous remote patient monitoring in patients with heart failure (cascade study): protocol for a mixed methods feasibility study | |
| US20230083562A1 (en) | Ai based methods and systems for tracking chronic conditions | |
| US20190080789A1 (en) | System for live monitoring of vitals for patients and physicians | |
| Paulson et al. | Treatment of a high healthcare utilizer with sepsis in a virtual hybrid hospital‐at‐home program | |
| Cafazzo et al. | The hospital at home: advances in remote patient monitoring | |
| Fiscella et al. | Aligning payment and policies with health care value and equity: blood pressure as a National Vital Sign | |
| van Uum et al. | How Dutch initiatives to early discharge COVID-19 patients were organised during the pandemic: a scoping review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08727737 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 0913333 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20080116 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 0913333.1 Country of ref document: GB |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08727737 Country of ref document: EP Kind code of ref document: A1 |